
Pulmonary Infection in the Immunocompromised Patient: Strategies for Management
by Editor: Carlos Agusti (Cap de Servei de Pneumologia i Al-lergia); Co-Editor: Antoni Torres (Cap de Servei de Pneumologia i Allergia)-
This Item Qualifies for Free Shipping!*
*Excludes marketplace orders.
Rent Textbook
New Textbook
We're Sorry
Sold Out
Used Textbook
We're Sorry
Sold Out
eTextbook
We're Sorry
Not Available
Summary
Table of Contents
Foreword | |
List of Contributors | |
Preface | |
Lung Immune Defences in the Immunosuppressed Patient | |
Introduction | |
Host defence function in health | |
Host defence function in select immunocompromised patients | |
Summary and future directions for this field | |
Microbiological Diagnosis of Respiratory Infections in the Immunocompromised | |
Introduction | |
HIV infection and Mycobacterium tuberculosis | |
HIV infection and Non Tuberculous Mycobacteria | |
HIV and Pneumocystis jirovecii | |
Infections in transplant patients or other immunodeficiencies | |
Concluding remarks | |
Diagnosis of Pneumonia in Immunocompromised Patients | |
Introduction | |
Clinical assessment | |
Blood cultures | |
Sputum | |
Endotracheal aspirate | |
Non bronchoscopic bronchoalveolar lavage | |
Protected brush sample (PBS) | |
Bronchoalveolar lavage (BAL) | |
Transbronchial biopsy (TBB) | |
Surgical lung biopsy (SLB) | |
Sample processing | |
Clinical approach to pulmonary infiltrates in immunosuppressed patient | |
Conclusion | |
Pulmonary Imaging in Immunocompromised Patients | |
Pulmonary infections in immunocompromised patients | |
Respiratory infections | |
Interventional procedures in patients with pneumonia | |
Summary | |
Pulmonary Infections in HIV Patients in the Highly Active Antiretroviral Therapy Era | |
Introduction | |
Epidemology and etiology | |
Diagnosis | |
Prognosis | |
Conclusions | |
Neutropenia | |
Introduction | |
Management of the neutropenic patient | |
Specific infectious diseases | |
General Management of Suspected Pneumonia in the Solid Organ Transplant Paitent | |
Introduction | |
Epidemiology | |
Differential diagnosis and non-infectious complications | |
Diagnostic approach | |
Conclusion | |
Respiratory Infections Following Haematopoietic Stem Cell Transplantation | |
Immune system recovery after HSCT | |
Bacterial pneumonia | |
Invasive pulmonary aspergillosis | |
Cytomegalovirus | |
Community respiratory viruses | |
Non-infectious pulmonary complications | |
Conclusion | |
Chronic Non-infectious Pulmonary Complications in Haematopoietic Stem Cell Transplantation | |
Introduction | |
Bronchiolitis Obliterans (BO) | |
Bronchiolitis Obliterans organizing pneumonia (BOOP) | |
Idiopathic pneumonia syndrome (IPS) | |
Diffuse alveolar haemorrhage (DAH) | |
Peri-engraftment respiratory distress syndrome (PERDS) | |
Delayed pulmonary toxicity syndrome (DPTS) | |
Pulmonary cytolytic thrombi (PCT) | |
Other non-infectious pulmonary complications | |
Summary | |
Pulmonary Infections in Patients on Chronic Glucocorticoid Treatment | |
Introduction | |
Associated inflammatory response in pneumonia | |
Glucocorticoids: mechanisms of action | |
Glucocorticoid therapy in clinical practice | |
Diagnostic approach | |
Empirical treatment of suspected pneumonia in patients receiving chronic GC therapy | |
Prognosis | |
Conclusions | |
Intensive Care Management in the Immunocompromised Patient with Pulmonary Infiltrates | |
Introduction | |
Invasive ventilation | |
Rationale for NIV | |
Mechanisms of improvement with NIV in immunocompromised patients with acute respiratory failure | |
Clinical studies | |
Equipment and techniques: particularities in immunocompromised patients | |
Predictive factors of NIV outcome | |
Conclusions | |
Current Strategies and Future Directions in Antibacterial Treatment | |
Introduction | |
Farmacokinetics and farmacodynamics | |
Antibacterial treatment options | |
Resistance | |
HIV related bacterial pulmonary infections | |
Length of treatment | |
Conclusions | |
Current Strategies in the Treatment of Fungal Infections in the Intensive Care Unit Setting | |
Introduction | |
Antifungal therapies | |
The endemic fungi in the critical care unit | |
Other yeast infections in the critical care unit | |
Invasive mould infections in the critical care unit | |
Summary | |
Current Strategies and Future Directions in Cytomegalovirus (CMV) Pneumonitis | |
Effects of CMV infection in immunocompromised patients | |
Pathophysiology of CMV pneumonitis | |
Risk factors for CMV pneumonitis | |
Pulmonary manifestations of CMV infection | |
Indirect respiratory effects of CMV infection | |
Diagnosis of CMV pneumonitis | |
Antiviral agents against CMV | |
Treatment of CMV pneumonia | |
Prevention of CMV pneumonia | |
Antiviral Agents against Respiratory Viruses | |
M2 inhibitors | |
Neuraminidase inhibitors | |
Cidofovir | |
Ribavirin | |
Investigational agents | |
Index | |
Table of Contents provided by Publisher. All Rights Reserved. |
An electronic version of this book is available through VitalSource.
This book is viewable on PC, Mac, iPhone, iPad, iPod Touch, and most smartphones.
By purchasing, you will be able to view this book online, as well as download it, for the chosen number of days.
Digital License
You are licensing a digital product for a set duration. Durations are set forth in the product description, with "Lifetime" typically meaning five (5) years of online access and permanent download to a supported device. All licenses are non-transferable.
More details can be found here.
A downloadable version of this book is available through the eCampus Reader or compatible Adobe readers.
Applications are available on iOS, Android, PC, Mac, and Windows Mobile platforms.
Please view the compatibility matrix prior to purchase.